Category Archives: Genetic Medicine

23-06-2012 23:24 Dr Rima Laibow Speaks on Codex Alimentarius Global Eugenics -- Using Medicine To Kill' is a feature length documentary using a collaboration of various materials. It covers topics such as the swine flu, vaccines and vaccinations, quarantine, water, depopulation, eugenics, Monsanto, gm seeds, Agenda 21, and Codex Alimentarius. In 2008, BA Brooks, a director specialized in meanwhile at The New York Film Academy in the creation of digital movies, launched his first exclusive documentary created with videos downloaded from YouTube, a technique that was used successfully in the documentary at hand, Global EUGENlCS -- Using Medicine to Kill, from 2009, which in over two hours of footage, he could afford to treat a wide range of topics: the avian flu and swine and their possible genetic manipulation, the vaccines and the aggressive vaccination campaigns, the origins of AIDS / HIV , martial law, medical news, water, GD Searle and genetically modified food, Agenda 21 -- the imposition of "sustainable development", HR 875 -- the legislation enforcement of the Codex Alimentarius in the US and others, all of which can be grouped under a single logo -- eugenic politics.

Original post:
Dr Rima Laibow 2/4 Speaks on Codex Alimentarius - Video

TAMPA Imagine being able to use a person's unique genetic code to find the right treatment for heart failure, asthma or even the dreaded common cold.

That's the focus of Dr. Stephen Liggett, one of the newest additions to the University of South Florida's Morsani College of Medicine.

Liggett, 57, began work this month as director of the USF Health Personalized Medicine Institute. He is a national leader in the emerging field and has attracted millions in research dollars from the National Institutes of Health.

One of his first orders of business will be to collaborate with Dr. Leslie Miller, head of the USF Health Heart Institute, which this spring received $8.9 million in state and county funding to begin developing genomics-based personalized approaches to cardiovascular care.

Liggett comes to USF from the University of Maryland, where he was a professor of medicine and physiology and director of its cardiopulmonary genomics program.

We caught up with Liggett during his first week on the job:

What is personalized medicine?

It's the use of information obtained from an individual's genetic code, or genome, to tailor their medical care. There are three areas where genomic information is particularly useful:

The prediction of whether a person is at risk for developing a disease.

The ability to predict the course, or degree of severity, of a disease in patients.

Original post:
National leader in personalized medicine heads new institute at USF Health

Public release date: 21-Jun-2012 [ | E-mail | Share ]

Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press

A pioneering report of genome-wide gene expression in autism spectrum disorders (ASDs) finds genetic changes that help explain why one person has an ASD and another does not. The study, published by Cell Press on June 21 in The American Journal of Human Genetics, pinpoints ASD risk factors by comparing changes in gene expression with DNA mutation data in the same individuals. This innovative approach is likely to pave the way for future personalized medicine, not just for ASD but also for any disease with a genetic component.

ASDs are a heterogeneous group of developmental conditions characterized by social deficits, difficulty communicating, and repetitive behaviors. ASDs are thought to be highly heritable, meaning that they run in families. However, the genetics of autism are complex.

Researchers have found rare changes in the number of copies of defined genetic regions that associate with ASD. Although there are some hot-spot regions containing these alterations, very few genetic changes are exactly alike. Similarly, no two autistic people share the exact same symptoms. To discover how these genetic changes might affect gene transcription and, thus, the presentation of the disorder, Rui Luo, a graduate student in the Geschwind lab at UCLA, studied 244 families in which one child (the proband) was affected with an ASD and one was not.

In addition to identifying several potential new regions where copy-number variants (CNVs) are associated with ASDs, Geschwind's team found genes within these regions to be significantly misregulated in ASD children compared with their unaffected siblings. "Strikingly, we observed a higher incidence of haploinsufficient genes in the rare CNVs in probands than in those of siblings, strongly indicating a functional impact of these CNVs on expression," says Geschwind. Haploinsuffiency occurs when only one copy of a gene is functional; the result is that the body cannot produce a normal amount of protein. The researchers also found a significant enrichment of misexpressed genes in neural-related pathways in ASD children. Previous research has found that these pathways include other genetic variants associated with autism, which Geschwind explains further legitimizes the present findings.

###

Luo et al.: "Genome-wide Transcriptome Profiling Reveals the Functional Impact of Rare De Novo and Recurrent CNVs in Autism Spectrum Disorders."

ABOUT THE AMERICAN JOURNAL OF HUMAN GENETICS

The American Journal of Human Genetics (AJHG) is ASHG's official scientific journal, published by Cell Press. AJHG is the most highly regarded peer-reviewed journal dedicated to studies in human genetics and earned an impact factor of 11.680 in 2011. AJHG provides cutting-edge research and review articles related to genetics and genomics and the application of genetic principles in health, disease, medicine, population studies, evolution, and societal impacts. For more information about AJHG, visit: http://www.ajhg.org.

Go here to read the rest:
Study explains functional links between autism and genes

19-06-2012 13:51 Aida Bytyçi is a certified genetic counselor at the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University in the US. Her time is divided between providing genetic counseling to patients and working on several research projects, such as one attempting to sequence the whole human genome to identify genes responsible for inherited syndromes and health conditions. As a genetic counselor, Aida provides support and advice to patients and their families on the inheritance and consequences of the genetic disorder. In this ideal position between research and patient care, Aida orients herself with the polar star of creative innovation brought by science and art. She believes that these two disciplines stimulate the mind and require a developed imagination to bring change in people's lives. At TEDxPrishtina Aida tells the greatest story ever written in four letters: A, T, C, and G. These four nucleotides that make the DNA code are the core of the greatest book ever written, the Human Genome. AboutTEDx, x=independently organized event In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x=independently organized TED event. The TED Conference provides general guidance for the TEDx program, but ...

Follow this link:
TEDxPrishtina - Aida Bytyçi - Video

19-06-2012 15:05 The SickKids Centre for Genetic Medicine is bringing together the brightest minds in patient care, education, policy and research with the goal of one day making individualized treatment a standard of care for all children. The Centre for Genetic Medicine has the potential to have a significant impact on the health of children, as 90 per cent of chronic diseases have a genetic component and known genetic diseases account for over half of hospital admissions.

See the article here:
The SickKids Centre for Genetic Medicine - Video

Newswise LOS ANGELES (June 19, 2012) Cedars-Sinais Regenerative Medicine Institute has pioneered research on how motor-neuron cell-death occurs in patients with spinal muscular atrophy, offering an important clue in identifying potential medicines to treat this leading genetic cause of death in infants and toddlers.

The study, published in the June 19 online issue of PLoS ONE, extends the institutes work to employ pluripotent stem cells to find a pharmaceutical treatment for spinal muscular atrophy or SMA, a genetic neuromuscular disease characterized by muscle atrophy and weakness.

With this new understanding of how motor neurons die in spinal muscular atrophy patients, we are an important step closer to identifying drugs that may reverse or prevent that process, said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute.

Svendsen and his team have investigated this disease for some time now. In 2009, Nature published a study by Svendsen and his colleagues detailing how skin cells taken from a patient with the disorder were used to generate neurons of the same genetic makeup and characteristics of those affected in the disorder; this created a disease-in-a-dish that could serve as a model for discovering new drugs.

As the disease is unique to humans, previous methods to employ this approach had been unreliable in predicting how it occurs in humans. In the research published in PLoS ONE, to the team reproduced this model with skin cells from multiple patients, taking them back in time to a pluripotent stem cell state (iPS cells), and then driving them forward to study the diseased patient-specific motor neurons.

Children born with this disorder have a genetic mutation that doesnt allow their motor neurons to manufacture a critical protein necessary for them to survive. The study found these cells die through apoptosis the same form of cell death that occurs when the body eliminates old, unnecessary as well as unhealthy cells. As motor neuron cell death progresses, children with the disease experience increasing paralysis and eventually death. There is no effective treatment now for this disease. An estimated one in 35 to one in 60 people are carriers and about in 100,000 newborns have the condition.

Now we are taking these motor neurons (from multiple children with the disease and in their pluripotent state) and screening compounds that can rescue these cells and create the protein necessary for them to survive, said Dhruv Sareen, director of Cedars-Sinais Induced Pluripotent Stem Cell Core Facility and a primary author on the study. This study is an important stepping stone to guide us toward the right kinds of compounds that we hope will be effective in the model and then be reproduced in clinical trials.

The study was funded in part by a $1.9 million Tools and Technology grant from the California Institute for Regenerative Medicine aimed at developing new tools and technologies to aid pharmaceutical discoveries for this disease.

# # #

Excerpt from:
Researchers, with Stem Cells, Advance Understanding of Spinal Muscular Atrophy